Atara Biotherapeutics Inc (ATRA)

NASDAQ
3.44
+0.06(+1.78%)
After Hours
3.44
0.00(0.00%)
- Real-time Data
  • Volume:
    2,228,525
  • Day's Range:
    3.17 - 3.45
  • 52 wk Range:
    2.83 - 20.04
Earnings results expected tomorrow

ATRA Overview

Prev. Close
3.38
Day's Range
3.17-3.45
Revenue
24.1M
Open
3.3
52 wk Range
2.83-20.04
EPS
-3.65
Volume
2,228,525
Market Cap
321.32M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,004,947
P/E Ratio
-
Beta
1.49
1-Year Change
-72.78%
Shares Outstanding
93,405,726
Next Earnings Date
Aug 08, 2022
What is your sentiment on Atara Biotherapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Atara Biotherapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Atara Biotherapeutics Inc Analysis

Atara Biotherapeutics Inc Company Profile

Atara Biotherapeutics Inc Company Profile

Employees
578

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. Its platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). The Company’s pipeline products include Tab-cel, ATA188, ATA2271, ATA3271 and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is a T-cell immunotherapy for the treatment of multiple sclerosis.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
  • my target- 70$
    1
    • BRIEF-Atara Biotherapeutics - Entered Into Sales Agreement For Offering Of Up To $100 MillionNov 26 (Reuters) - Atara Biotherapeutics Inc:* ATARA BIOTHERAPEUTICS - ENTERED INTO SALES AGREEMENT FOR OFFERING OF UP TO $100 MILLION
      0
      • trash ?
        0
        • What has happened to ATRA?
          1
          • What has happened to ATRA?
            0
            • Issues more stocks
              0
          • what has happened?
            0
            • 🚀🔥Requires reading! Bayer pays Atara bio $ atra an advance of $ 60mil and potentially $ 600 mil + royalties with a percentage of future sales towards its target Mesothelin. They enter into strategic partnerships 🚀🔥 - we are waiting for the opening of 🇷🇺 our session and the US session 🇺🇸. There should be a jerk up 🚀, pumps and gaps with closure are possible.
              0
              • According to IR, $ATRA won't be issuing secondary any time soon. Possibly after the successful Phase 3 test.. It's a BUY!
                1